中文摘要：

目的 研究肿瘤坏死因子相关凋亡诱导配体（TRAIL）及其受体TRAIL-R2和TRAIL-R4在非小细胞肺癌（NSCLC）中的表达及其意义.方法 采用酶联免疫吸附试验（ELISA）检测79例NSCLC患者与80例正常人血清中TRAIL的表达水平,采用免疫组织化学法检测42例NSCLC组织及配对癌旁正常组织中TRAIL-R2和TRAIL-R4的表达水平.分析TRAIL、TRAIL-R2、TRAIL-R4与NSCLC患者临床病理特征的关系.结果 TRAIL在NSCLC患者血清中的表达明显低于正常人[（994.3±293.0） ng/ml∶（1 141.7 ±266.1） ng/ml],差异具有统计学意义（t=3.29,P=0.00）.TRAIL的表达与NSCLC患者的临床分期（F=2.28,P=0.00）、分化程度（t=5.76,P=0.00）相关.TRAIL-R2在NSCLC组织中的阳性表达率为73.8％ （31/42）,明显低于正常组织中的阳性表达率100.0％ （42/42）（x2=3.88,P=0.05）,TRAIL-R2的表达与NSCLC患者的临床分期（x2=27.89,P=0.00）、分化程度（x2=9.50,P=0.00）相关.TRAIL-R4在NSCLC组织中的阳性表达率为81.0％ （34/42）,明显高于正常组织中的阳性表达率50.0％（21/42）（x2=7.34,P=0.01）,TRAIL-R4的表达与NSCLC患者的临床分期（x2=17.82,P=0.00）、分化程度（x2=4.47,P=0.03）相关.在NSCLC组织中,TRAIL-R4与TRAIL-R2的表达呈负相关（r=-0.67,P=0.01）.结论 在NSCLC中,TRAIL、TRAIL-R2表达减少,TRAIL-R4表达增多,三者可能促进了NSCLC的发生发展,可为NSCLC临床治疗提供靶点.

英文摘要：

Objective To investigation the expressions of tumor necrosis factor-related apoptosis-inducing ligand （TRAIL） and its receptors in non-small cell lung cancer （NSCLC） and their clinical significances.Methods The serum expression levels of TRAIL in 79 cases of NSCLC and 80 cases of normal subjects were detected by enzyme-linked immunosorbent assay （ELISA）.The expressions of TRAIL-R2 and TRAIL-R4 in 42 cases of NSCLC and matched normal tissues were detected by immunohistochemistry.The relationships among TRAIL,TRAIL-R2,TRAIL-R4 and clinicopathologic features of NSCLC were analyzed.Results The expression of TRAIL in NSCLC patients was lower than that in normal human [（994.3 ±293.0）ng/ml vs.（1 141.7 ±266.1）ng/ml,t =3.29,P =0.00].The expression of TRAIL was closely correlated with clinical stage （F =2.28,P =0.00） and differentiated degree （t =5.76,P =0.00）.The positive expression rate of TRAIL-R2 in NSCLC was 73.8％ （31/42）,significantly lower than that in the normal tissue 100.0％ （42/42） （x2 =3.88,P =0.05）.The expression of TRAIL-R2 was closely correlated with clinical stage （x2 =27.89,P=0.00） and differentiated degree （x：=9.50,P =0.00）.The positive expression rate of TRAIL-R4 in NSCLC was 81.0％ （34/42）,significantly higher than that in the normal tissue 50.0％ （21/42） （x2 =7.34,P =0.01）.The expression of TRAIL-R4 was also closely correlated with clinical stage （x2 =17.82,P =0.00） and differentiated degree （x2 =4.47,P =0.03）.There was a negative correlation between the expression of TRAIL-R2 and TRAIL-R4 in NSCLC （r =-0.67,P=0.01）.Conclusion The decrease of TRAIL and TRAIL-R2 and increase of TRAIL-R4 expression may promote the occurrence and development of NSCLC,and they may provide targets for clinical treatment of NSCLC.